Egis in the World

Our products reach 100 countries

Click here to learn more

Pharma Company

Our activities incorporate all areas of the pharmaceutical value chain

Click here to learn more

Research & Development

Innovation is one of the pillars of our strategy. We devoted EUR 48 million to research and development in the 2022/2023 business year.

Click here to learn more
Own subsidiaries / Representative offices
Sales through Partners
Egis World

Celebrating our company’s 110th anniversary

The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.

More
Egis World

Dr Csaba Pácz confirmed as Commercial Director of Egis Group

The selection process for the position of Egis Group’s Commercial Director has been closed. As a result, dr Csaba Pácz remains head of the Commercial Directorate.

More
Egis World

Csaba Poroszlai is CEO of Egis Pharmaceuticals PLC

Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.

More
More articles

Egis in the World

Egis’ products reach 100 countries around the world.

Egis ’products reach countries. Our portfolio consists of 653 products.  Our main focus lies on treating diseases of the cardiovascular and central nervous systems.

Learn more

A place to work

Join us!

Healthcare Professionals

and prescription drugs

Professional content for our medical and pharmaceutical visitors. These contents are available with password protection - please contact our representative or require your own account at the Contact menu.

Learn more
Therapeutic areas
Therapeutic areas
Allergology
Cardiovascular system
Central nervous system
Gastroenterology
Women´s health
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox